- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02451189
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis (PRO-ESTER)
April 27, 2016 updated by: Dr Douglas Morrison, Scottish Universities Environmental Research Centre
Obesity, with its associated co-morbidities, is a major public health challenge.
It is estimated that by 2050, 60% of men and 50% of women will be clinically obese.
Obesity is associated with increased risk of developing diabetes, cardiovascular disease, and certain cancers.
The increasing epidemic of obesity has necessitated the study of the complex mechanisms underlying energy homeostasis.
Food intake, energy balance and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status.
Several gut hormones, including glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY), have been shown to play an important role in regulating short-term food intake.
Peripheral administration of PYY or GLP-1 enhances satiety and reduces food intake in animals and man.
PYY, GLP-1 along with a host of other hormones are produced by the gut in response to nutrient availability in different regions of the gut and provide an exquisite mechanism of nutrient sensing in response to dietary intake.
These hormones therefore represent potential targets in the development of novel anti-obesity treatments.
A novel and attractive strategy to induce appetite regulation is the enrichment of foods with components that stimulate the release of GLP-1 and PYY.
The short chain fatty acids (SCFA) produced by microbial fermentation of dietary fibre in the colon have been shown to stimulate the release of PYY and GLP-1 from rodent enteroendocrine L cells, via stimulation of the G-protein coupled free fatty acid receptors (FFAR) on colonic L cells.
However, it is not known whether the three SCFA, acetate, butyrate and propionate, differentially affect appetite and glucose control.
The aim of this study is to compare the effects of increased colonic delivery of acetate, butyrate and propionate on appetite and glucose control in overweight men in a randomised crossover study.
Study Overview
Status
Completed
Conditions
Detailed Description
The role of SCFA in appetite regulation: SCFA have been shown to stimulate PYY and GLP-1 production in animal models and dietary fibre, of which SCFA are the major end products, induce appetite regulation in humans.
However the evidence underpinning which dietary fibres induce appetite regulation in humans is very weak because of the difficulty in controlling studies with very high fibre intake.
In a recent project funded under the BBSRC DRINC initiative (BB/H004815/1), the investigators have the first direct evidence that SCFA can directly regulate appetite in humans.
Prior to this study, in order to achieve production of SCFA to a level, which is high enough to induce appetite-regulating effects, very large amounts of dietary fibre (>25 g/d and up to 40 g/d) are required, and compliance with high fibre diets is poor due to gastrointestinal side effects.
Furthermore, supplementing diets with mixed high fibre does not predictably or reliably increase colonic SCFA production or circulating levels of SCFA in all human populations because of the variability in gut microbial activity.
Finally, orally administered SCFAs are not palatable and are rapidly absorbed in the small intestine where L cells are sparse.
In our studies to date we have focussed on the SCFA propionate because it has the highest affinity for the receptors and is an end product of metabolism in the microbiota and therefore seems the obvious target to manipulate to investigate the effects of SCFA on appetite regulation.
To overcome the unpalatably high levels of fermentable dietary fibre needed to significantly increase colonic propionate levels, and the unpredictability in the production of the resulting SCFAs, the investigators have developed and tested a novel delivery system targeting the release of gram quantities of propionate in the proximal colon.
It is estimated that the delivery system may lead to a 2-8 fold increase in colonic propionate, a level very difficult to achieve through feeding a mixed fermentable fibre diet.
This level of propionate production might have been observed in ancestral diets and in parts of rural Africa where dietary fibre intake is very high.
Previous work, conducted by the investigators, has also demonstrated that delivery system increases plasma propionate levels, reduces food intake in acute studies of appetite, and in a longer term study (24 weeks), positive effects on food intake, body composition, glucose homeostasis, circulating lipids, cholesterol and liver function, liver and visceral fat and weight management were observed.
However, at present it is not known if acetate, propionate and butyrate exert similar effects on appetite and glucose metabolism.
Therefore in this study we wish to compare the the effects of targeted delivery of acetate, propionate and butyrate to the proximal colon on appetite and glucose homeostasis in overweight men.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Lanarkshire
-
Glasgow, Lanarkshire, United Kingdom, G4 0SF
- Glasgow Clinical Research Facility
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and Female
- Healthy
- Overweight (BMI 25-40 kg/m2)
Exclusion Criteria:
- Weight change of > 3kg in the preceding 2 months
- Current smokers
- Substance abuse
- Excess alcohol intake
- Diabetes
- Cardiovascular disease
- Cancer
- Gastrointestinal disease
- Kidney disease
- Liver disease
- Pancreatitis
- Use of any medication except contraceptive pill
- Peri-menopausal
- Pregnancy
- Breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inulin acetate ester
Inulin acetate ester, 10g/day for 30 days
|
Inulin acetate ester supplementation (10g/d) for 30 days.
Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
|
Experimental: Inulin propionate ester
Inulin propionate ester, 10g/day for 30 days
|
Inulin propionate ester supplementation (10g/d) for 30 days.
Appetite measurements on day 15 and OGTT on day 30.
|
Experimental: Inulin butyrate ester
Inulin butyrate ester, 10g/day for 30 days
|
Inulin butyrate ester supplementation (10g/d) for 30 days.
Appetite measurements on day 15 and OGTT on day 30.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Energy intake at ad libitum meal
Time Frame: 8 hours
|
Energy intake is measured at an ad libitum meal
|
8 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective appetite sensations
Time Frame: 8 hours
|
Appetite is rated on 100 mm visual analogue scales
|
8 hours
|
Plasma glucose and insulin
Time Frame: 2 hours
|
Oral glucose tolerance test: Fasting and 2h glucose and insulin concentrations following consumption of solution providing 75g glucose
|
2 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intestinal bacteria composition
Time Frame: 24 hours
|
Faecal samples will be collected to assess the impact of the NDC esters on gut bacteria composition
|
24 hours
|
Lipids
Time Frame: 8 hours
|
Serum triglycerides and cholesterol concentrations will be determined
|
8 hours
|
Appetite regulating gut hormones
Time Frame: 8 hours
|
Fasting and postprandial gut hormone concentrations will be measured
|
8 hours
|
Liver function test
Time Frame: 1hour
|
1hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Douglas Morrison, PhD, Scottish Universitites Environmental Research Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
May 19, 2015
First Submitted That Met QC Criteria
May 20, 2015
First Posted (Estimate)
May 21, 2015
Study Record Updates
Last Update Posted (Estimate)
April 28, 2016
Last Update Submitted That Met QC Criteria
April 27, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-ESTER STUDY
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Inulin acetate ester
-
Imperial College LondonCompleted
-
University of GlasgowCompletedExercise | Inulin Propionate Ester
-
KU LeuvenCompletedShort Chain Fatty Acids BioavailabilityBelgium
-
Insel Gruppe AG, University Hospital BernWithdrawn
-
BHB Therapeutics, Ireland LTDMérieux NutriSciences BiofortisCompleted
-
Eskisehir Osmangazi UniversityUnknownFunctional Constipation
-
Maastricht University Medical CenterCompleted
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Imperial College LondonUniversity of GlasgowCompletedAppetite Regulation | Healthy Obesity, MetabolicallyUnited Kingdom
-
University of Illinois at Urbana-ChampaignRenal Research InstituteCompletedBone Diseases, Endocrine | Nutritional and Metabolic DiseasesUnited States